Breo Ellipta vs Xolair
A side-by-side look at two respiratory medications advertised on TV. Informational only — not medical advice.
| US Breo Ellipta | US Xolair | |
|---|---|---|
| Generic name | fluticasone/vilanterol | omalizumab |
| Drug class | ICS/LABA Inhaler | Anti-IgE Monoclonal Antibody |
| Treats | Asthma, COPD | Allergic asthma, chronic hives, food allergy |
| Category | Respiratory | Respiratory |
| Manufacturer | GSK | Genentech/Novartis |
| Year approved | 2013 | 2003 |
| FDA warning | No boxed warning | Black box warning |
| Est. TV ad spend | $100M | $95M |
| Common side effects | Oral thrush, Throat irritation, Headache, Common cold symptoms | Anaphylaxis (severe allergic reaction), Injection site reactions, Joint pain, Headache |
Breo Ellipta
Frequently asked questions
Is Breo Ellipta or Xolair better?
Neither is universally "better." Breo Ellipta (fluticasone/vilanterol) and Xolair (omalizumab) are both used for respiratory, but the right choice depends on your medical history, insurance and your doctor's guidance. This comparison is informational only.
What's the difference between Breo Ellipta and Xolair?
Breo Ellipta is a ICS/LABA Inhaler made by GSK, while Xolair is a Anti-IgE Monoclonal Antibody made by Genentech/Novartis. See the table above for a side-by-side breakdown.
Which one spends more on TV ads?
Breo Ellipta has the larger estimated TV advertising budget of the two.